

December 23, 2025

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,  
The Manager – Listing,  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Dear Sir,

**Sub: Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial**

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029.

Kindly find attached media release which is self- explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

*Encl: As above*

**Glenmark Pharmaceuticals Limited**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

## **Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial**

**Elmwood Park, New Jersey, December 23, 2025** – Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch<sup>1</sup> of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029.

According to IQVIA<sup>TM</sup> sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market<sup>2</sup> achieved annual sales of approximately \$67.6 million\*.

**Commenting on the launch, Marc Kikuchi, President & Business Head, North America said,** "We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."

<sup>1</sup>Glenmark's Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is only approved for the indication(s) listed in Glenmark's approved label.

<sup>2</sup>Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications.

\*IQVIA<sup>TM</sup> National Sales Perspectives: Retail & Non-Retail, October 2025

### **About Glenmark Pharmaceuticals Limited**

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 4.5 million lives over the last decade through its CSR interventions. For more information, visit [www.glenmarkpharma.com](http://www.glenmarkpharma.com). You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (Glenmark\_pharma).

# Press Release

For Immediate Distribution



For more information, please contact

Aakanksha Pilay | [mediarelations@glenmarkpharma.com](mailto:mediarelations@glenmarkpharma.com) | +91 7218171062

Adfactors PR | [glenmark@adfactorspr.com](mailto:glenmark@adfactorspr.com) | +91 88502 91322